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Abstract
Background: Population-based studies historically report underutilization of a resection in patients
with colorectal metastases to the liver. Recent data suggest limitations of the methods in the historical
analysis. The present study examines trends in a hepatic resection and survival among Medicare recip-
ients with hepatic metastases.
Methods: Medicare recipients with incident colorectal cancer diagnosed between 1991 and 2009
were identified in the SEER(Surveillance, Epidemiology and End Results)-Medicare dataset. Patients
were stratified into historical (1991–2001) and current (2002–2009) cohorts. Analyses compared treat-
ment, peri-operative outcomes and survival.
Results: Of 31 574 patients with metastatic colorectal cancer to the liver, 14 859 were in the current
cohort treated after 2002 and 16 715 comprised the historical control group. The overall proportion
treated with a hepatic resection increased significantly during the study period (P < 0.001) with pre/
post change from 6.5% pre-2002 to 7.5% currently (P < 0.001). Over time, haemorrhagic and
infectious complications declined (both P ≤ 0.047), but 30-day mortality was similar (3.5% versus
3.9%, P = 0.660). After adjusting for predictors of survival, the use of a hepatic resection [hazard ratio
(HR) = 0.40, 95% confidence interval (CI): 0.38–0.42, P < 0.001] and treatment after 2002 (HR = 0.88,
95% CI: 0.86–0.90, P < 0.001) were associated with a reduced risk of death.
Conclusions: Case identification using International Classification of Diseases, 9th Revision (ICD-9)
codes is imperfect; however, comparison of trends over time suggests an improvement in multimodal-
ity therapy and survival in patients with colorectal metastases to the liver.
Received 24 March 2015; accepted 1 July 2015
Correspondence
Victor M. Zaydfudim, MD, MPH, Hepatobiliary and Pancreatic Surgery, University of Virginia,
Box 800709, Charlottesville, VA 22908-0709, USA. Tel.: +1 434 924 2839. Fax: +1 434 982 4778. E-mail:
vz8h@virginia.edu
Introduction
Colorectal cancer (CRC) is the most common gastrointestinal
malignancy, most common potentially resectable metastatic
tumour to the liver and the most common indication for a
liver resection in the United States. Up to 50% of patients with
primary CRC will develop liver metastases in their lifetime
with up to 20% of these patients eligible for a hepatic metasta-
sectomy at high-volume centres.1–3 With advances in operative
techniques, peri-operative management and multi-modality
therapy, nationwide post-operative mortality after a liver resec-
tion approaches 2–5%.4–6 From a population-based perspec-
tive, only a minority of patients with hepatic metastases from
CRC complete a metastasectomy.
The differences between institutional and population-level
data have been difficult to reconcile. Unlike the 20% resection
rate reported at select high-volume referral centres, a hepatic
metastasectomy was performed in 6% of Medicare beneficiaries
with the diagnosis of hepatic metastases from colorectal cancer
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prior to 2002.3,7 This discrepancy is likely multifactorial and
attributable to both patient and physician-specific factors.
Recent nationwide inpatient data suggests increased utilization
of a hepatic metastasectomy for patients with colorectal cancer;
however, current resection rates have not been established.8
The linked SEER (Surveillance, Epidemiology and End
Results)-Medicare database allows for the population-based
identification of incident cancer cases and the follow-up of
patient care through time. Previously published SEER-Medi-
care data summarizing patient data between 1991 and 2001
identified a potential underutilization of operative treatment in
patients with hepatic metastases from colorectal cancer.7 This
study has been cited extensively in both hepatobiliary surgery
and public health and outcomes literature as evidence of
underutilization of hepatic resection among patients with
metastatic colorectal cancer. However, since its publication in
2007, the methodology used to assemble the study cohort has
been debated. Recent studies have emphasized limitations in
the detail of International Classification of Diseases, 9th Revi-
sion (ICD-9) codes in hospital claims data, with aggregated
accuracy of ICD-9 codes in diagnosis of metastatic colorectal
cancer estimated to approximate 80%.9–11
Despite the limitations of ICD-9 codes, SEER-Medicare is the
only United States national database to report both estimates of
patients treated (operation and/or chemotherapy) for metastatic
colorectal cancer to the liver and estimates of all patients with
this diagnosis. As such, comparison of historic (pre-2002) and
current hepatic resection rates using similar data acquisition
methods may provide helpful estimates in the use of treatment
for patients with metastatic CRC. Given ongoing advances in
multimodality management and peri-operative treatment of
patients with metastatic colorectal cancer to the liver, we
hypothesized a significant increase in the hepatic metastasec-
tomy rate for this patient population in the past decade.
Patients and methods
SEER and SEER-Medicare
The SEER programme is a the United States population-based
cancer registry supported by the National Cancer Institute
(NCI) and Centers for Disease Control and Prevention. The
current registry includes data collected from multiple localities
and states from 1973 to 2011. The most current reporting per-
iod includes data from 18 cancer registries drawn from
approximately 28% of the population of the United States.
The SEER-Medicare linked database is a collaboration
between NCI, SEER, and the Centers for Medicare and Medi-
caid Services. The SEER-Medicare database provides a combina-
tion of incident cancer cases and cancer-specific data collected
by SEER with Medicare claims data for covered health services
for Medicare beneficiaries identified from the SEER registry.
Specific Medicare claim files include Part A: Medicare Provider
Analysis and Review (MedPAR) hospital inpatient claims, and
Part B: carrier claims (physician/supplier claims) and outpatient
claims. The latest available data linkage at the time of data col-
lection was performed in 2012 and includes SEER incident data
through 2009 and Medicare claims through 2011.
Data collection and management
The data collection and study design were reviewed and
approved by the University of Virginia Institutional Review
Board. We conducted a retrospective, population-based cohort
study of all patients diagnosed with colorectal adenocarcinoma
using the SEER registry coding system. Patients included in the
study had the following combination of characteristics: ICD-0-
3 histology code adenocarcinoma (8140/1-3) and primary
pathology sites colon (C15-23) and anorectum (C25-27)
between 1991 and 2009, who also had a Medicare diagnosis of
malignant neoplasm of the liver, secondary (ICD-9-CM 197.7)
between 1991 and 2011 using the MedPAR, carrier claims and
outpatient claims data. The study population was dichoto-
mized into historical and current cohorts, based on data pub-
lished previously summarizing outcomes for 1991 to 2001
SEER-Medicare patients.7 The historical cohort included
patients diagnosed with colorectal cancer between 1991 and
2001. The current cohort included patients diagnosed with col-
orectal cancer between 2002 and 2009.
Patients who were enrolled in a Medicare HMO or not
enrolled in Medicare Part B in the 2 years from the date of
colon cancer diagnosis were excluded, as were patients with
the previous metastatic disease. Patients less than 66 years of
age at the time of diagnosis were also excluded in order to
ensure all patients had at least 1 year of Medicare claims pre-
ceding diagnosis. Patients who did not complete a colorectal
resection were also excluded.
Demographic data included age, gender and race. Race was
classified as Caucasian, African–American or Other (Asian,
Hispanic, Unknown). Patient-specific comorbidities included
within 1 year of cancer diagnosis and present at least twice
within claims data were abstracted from MedPAR, carrier
claims, and outpatient claims and summarized as a Charlson/
Deyo comorbidity index as described previously.12,13 Patients
receiving systemic chemotherapy were identified using outpa-
tient claims for chemotherapy administration within 6 months
of the diagnosis of hepatic metastases. Chemotherapy adminis-
tration was also identified for hepatic resection patients,
including both administration of chemotherapy 6 months
prior and/or 6 months after the liver resection.
Hepatic resections were identified using the ICD-9-CM diag-
nosis codes for a partial hepatectomy or wedge resection
(50.22), lobectomy of the liver (50.3), and total hepatectomy
(50.4), as well as, using Current Procedural Terminology
(CPT) procedure codes for a partial lobectomy (47120), triseg-
mentectomy (47122), total left lobectomy (47125) and total
right lobectomy (47130). The extent of a hepatic resection was
categorized as a partial hepatectomy (50.22 and/or 47120) and
a major (≥3 segments) anatomic hepatectomy (50.3, 50.4 and/
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or 47122, 47125, 47130). Post-operative complications were
abstracted from secondary diagnoses reported in MedPAR hos-
pital claims and were categorized into three groups as follows
(i) haemorrhagic complications: accidental laceration, post-op-
erative haemorrhage and post-haemorrhagic anaemia; (ii) gas-
trointestinal complications: paralytic ileus, gastrointestinal
complications, gastrointestinal haemorrhage and intestinal fis-
tula; and (iii) infectious complications: post-operative infec-
tion, wound dehiscence, peritonitis and liver abscess. For
patients with more than one liver operation, comorbidities and
complications associated with the first liver resection were
abstracted. Thirty-day post-operative mortality was abstracted
from Medicare data. The overall survival was calculated as
months between the diagnosis of hepatic metastases and death.
Statistical analysis
Distributional characteristics of data for continuous variables
are reported as medians with an interquartile range (IQR), and
as percentages for categorical data. The statistical significance
of differences between cohorts in the proportional distribution
of categorical variables was assessed using Pearson’s chi-square
test statistic. Differences in the median and mean values of
continuous variables between groups were compared with Wil-
coxon’s rank–sum test. A weighted linear regression was used
to represent graphically the change in hepatic resection rates
over time (weighted linear R2 = 0.673). Logistic regression
using a hepatic resection as the outcome and liver metastasis
diagnosis year as the predictor was used to estimate the change
in the hepatic resection rate over time. Kaplan–Meier survival
analysis, with the log–rank test for between-group compar-
isons, was used to test the bivariable effect of hepatic resection
on survival. Cox’s proportional hazards regression was used to
develop a multivariable model adjusting for the combined
effects of age, gender, race, incident AJCC stage at the time of
diagnosis, the Charlson/Deyo comorbidity index, hepatic resec-
tion, systemic chemotherapy and treatment time period on
survival in patients with colorectal cancer hepatic metastases.
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) soft-
ware was used to conduct data management, statistical analysis
and to produce plots of results. A P-value of <0.05 was consid-
ered to indicate statistically significant differences for all com-
parisons.
Results
Patient demographics and staging
Of 31 574 patients in the study cohort, 16 715 patients com-
prised the historical control group (1991–2001) and 14 859
patients comprised the current cohort (2002–2009). Demo-
graphic and clinical data are summarized in Table 1. Patients
in the current cohort had a higher median age, 78 (72–83) ver-
sus 77 (73–82) years, P = 0.040. Sex and race proportions were
not significantly different between the two groups. Patients in
the current cohort presented with higher AJCC stage (P <
0.001), and more patients in the current cohort had Stage III
and IV disease at the time of incident diagnosis. There was no
difference in the use of systemic chemotherapy within
6 months of the diagnosis of hepatic metastases (current
cohort: 33.0% versus historical cohort: 32.1%, P = 0.077).
Liver resection patients
Of 31 574 patients included in the study, 2190 (6.9%) under-
went a liver resection. The proportion of patients treated with
a liver resection increased during the entire study period with
a statistically significant yearly increase in odds each year: odds
ratio (OR) 1.03; 95% confidence interval (CI): 1.02–1.04, P <
0.001 (Fig. 1). The use of a liver resection increased from 1080
patients (6.5%) in the historical cohort to 1110 patients
(7.5%) in the current cohort (P < 0.001).
Peri-operative chemotherapy, operative extent, comorbidities
and post-operative complications are summarized in Table 2.
Patients in the current cohort had higher Charlson/Deyo
comorbidity index values (P < 0.001). Both the use of pre-op-
erative chemotherapy (22.3% versus 10.9%) and post-operative
chemotherapy (39.6% versus 31.5%) was higher in patients
treated after 2002 (both P < 0.001). The use of a major (≥3
segments) hepatectomy did not differ between the two time
periods (P = 0.974). The proportion of patients with post-hep-
atectomy complications was lower in the current cohort, with
fewer patients developing ≥ 1 complication after a resection
(25.5% versus 28.1%, P = 0.021). Both haemorrhagic and
infectious complications were significantly lower in the current
cohort (both P ≤ 0.047); gastrointestinal complications did not
differ between the two groups (P = 0.520). Post-operative 30-
Table 1 Demographic and clinical data of patients with colorectal
cancer hepatic metastases
Historical cohort
(1991–2001)
16 715 patients
Current cohort
(2002–2009)
14 859 patients
P-value
Age 77 (73–82) 78 (72–83) 0.040
Female 8671 (51.9) 7651 (51.5) 0.495
Race
Caucasian 13 788 (82.5) 12 126 (81.6) 0.052
African–American 1639 (9.8) 1578 (10.6)
Other 1288 (7.7) 1155 (7.8)
AJCC Stage at diagnosis
Stage I 1286 (7.7) 907 (6.1) <0.001
Stage II 3303 (19.8) 2291 (15.4)
Stage III 4686 (28.0) 4393 (29.6)
Stage IV 7440 (44.5) 7268 (48.9)
Chemotherapy 5357 (32.1) 4901 (33.0) 0.077
Data reported as n (%) except for the Age which is reported as median
(interquartile range).
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day mortality was 3.5% among the historical controls and
3.9% in the current cohort (P = 0.660).
Survival analyses
Patients treated with a hepatic resection had a better overall
survival compared with patients who did not complete a
hepatic metastasectomy in both cohorts (Fig. 2a, b), log–rank
P < 0.001. In the historical cohort, the median survival was
significantly better in patients completing a hepatic metastasec-
tomy (32 versus 7 months, log–rank P < 0.001). Similarly, the
median survival was significantly better among hepatic metas-
tasectomy patients in the current cohort (39 versus 8 months,
log–rank P < 0.001). The 5-year survival was significantly bet-
ter for patients selected for a metastasectomy during both
study periods (historical cohort: 26% vs. 6%; current cohort:
33% versus 7%; both P < 0.001).
Multivariable Cox’s proportional hazards regression analysis
was used to assess the adjusted effects of demographic and clin-
ical covariates on overall survival. The multivariable model is
summarized in Table 3. Age, Charlson/Deyo comorbidity index
and incident AJCC stage had independent negative effects on
survival (all P < 0.001). The use of systemic chemotherapy was
associated with a lower risk of death (HR = 0.64; 95% CI:
0.63–0.66; P < 0.001). Both the use of a hepatic resection (HR
= 0.40; 95% CI: 0.38–0.42, P < 0.001) and treatment in the
current study cohort (HR = 0.88; 95% CI: 0.86–0.90, P <
0.001) were also associated with a lower risk of death.
Discussion
Rates of hepatic metastasectomy for Stage IV colorectal cancer
continue to improve in Medicare recipients. Previously pub-
lished studies using SEER-Medicare registry reported 3.9% to
6.1% hepatic resection rates among patients with metastatic
colorectal cancer to the liver.7,14 The overall use of a hepatic
resection increased during the past decade with a current
aggregated resection rate of 7.5% for patients treated between
2002 and 2009. The use of peri-operative systemic chemother-
apy also increased between pre-2002 and current cohorts.
While the overall administration of chemotherapy in all
patients with hepatic metastases did not change with time and
is consistent with previously published SEER-Medicare data,15
the use of chemotherapy in patients selected for a metastasec-
tomy within 6 months prior to a liver resection increased from
10.9% to 22.3%, and the use of post-hepatectomy chemother-
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Figure 1 Logistic regression model demonstrating an improvement
in resection rates during the study period with a fitted estimated
resection rate (P < 0.001)
Table 2 Peri-operative data for a hepatic metastasectomy
Historical cohort (1991–2001)
1080 patients
Current cohort (2002–2009)
1110 patients
P-value
Age 74 (IQR: 71–78) 74 (IQR: 70–78) 0.056
Charlson/Deyo comorbidity index 0 (IQR: 0–1) (range: 0–6) 0 (IQR: 0–1) (range: 0–7) <0.001
Pre-metastasectomy chemotherapy 118 (10.9) 248 (22.3) <0.001
Post-metastasectomy chemotherapy 340 (31.5) 439 (39.6) <0.001
Operative extent
Partial hepatectomy 767 (71.0) 789 (71.1) 0.974
≥3 segments hepatectomy 313 (29.0) 321 (28.9)
≥1 complication 304 (28.1) 283 (25.5) 0.021
Haemorrhagic complicationsa 151 (14.0) 124 (11.2) 0.047
Gastrointestinal complicationsb 152 (14.1) 167 (15.1) 0.520
Infectious complicationsc 35 (3.2) 17(1.5) 0.009
30-day mortality 38 (3.5) 43 (3.9) 0.660
aAccidental laceration, post-operative hemorrhage and post-hAemorrhagic anaemia.
bParalytic ileus, gastrointestinal complications, gastrointestinal haemorrhage and intestinal fistula.
cPost-operative infection, wound dehiscence, peritonitis and liver abscess.
Data are reported as n (%) except for age which is reported as the median (interquartile range) and Charlson/Deyo comorbidity index which is
reported as the median (interquartile range and overall range).
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apy increased from 31.5% to 39.6%. Temporal treatment after
2002, a hepatic resection and chemotherapy were all indepen-
dently associated with an improved overall survival in patients
with hepatic metastases from colorectal cancer.
The use of resection and peri-operative chemotherapy in
Medicare recipients is increasing despite an aging patient popu-
lation with more comorbidities. The median age of patients
selected for a hepatic metastasectomy in this SEER-Medicare
study population of patients over 66 years at the time of diagno-
sis was 74 years; Charlson/Deyo comorbidity index values were
higher in patients treated between 2002 and 2009 than patients
treated prior to 2002. Despite a seemingly more aggressive treat-
ment approach, the frequency of overall, haemorrhagic and
infectious complications has declined. The 30-day post-operative
mortality remains less than 4% and is comparable to nationwide
National Surgical Quality Improvement Program data.4,6 Simi-
larly, long-term survival rates in patients selected for a metasta-
sectomy post-2002 are comparable to 30–40% 5-year overall
survival described in multi-institutional and nationwide
data.2,16,17
Unfortunately, identification of specific tumour features
affecting organ-specific or the overall metastatic burden and/or
disease biology is not possible with SEER-Medicare data. Defini-
tion of metastatic sites and/or disease recurrence using ICD-9
codes is limited. Sensitivity and the positive predictive value
(PPV) of distant CRC metastases using ICD-9 code definitions
are 80% and 70%, respectively, in historically reviewed SEER-
Medicare data.9 A corresponding diagnosis of CRC metastases
using ICD-9 data in proprietary claims databases achieves a PPV
between 73% and 80% and an overall accuracy of 80%.10,11 Also,
identification of colorectal cancer recurrence and/or presence of
metachronous metastases using ICD-9 data has a sensitivity of
71% and specificity of 91% among Medicare recipients.18 With
an overall accuracy approaching 80%, ICD-9 code definitions
alone are limited in defining patients with hepatic metastases.
However, despite this limitation, data acquisition methods are
believed to have been consistent between historic and current
study cohorts. Thus, even considering these limitations, our
results suggest an improvement of hepatic resection rates and in
the use of pre- and post-operative chemotherapy in Medicare
recipients with metastatic colorectal cancer.
Population-based analyses have other significant limitations.
The exact burden of disease and suitability of the operative
approach cannot be determined. To this extent, it is difficult
to compare 20% resection rates reported by institutional data
and a 7.5% resection rate in this population-based study. The
higher rates of resection in institutional data can reflect a refer-
ral bias of tertiary and quaternary care centres.19,20 In addition,
differences in the burden of disease and/or the significantly
older age of Medicare recipients can explain variability in the
resection rates between institutional and registry data. Interest-
ingly, a similar analysis among the patients enrolled in the
English National Health Service demonstrated improvement in
the hepatic metastasectomy rate from 1.7% in 1998 to 3.8% in
2004.20
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Figure 2 (a) Survival by a hepatic metastasectomy in the historic
cohort (1991–2001). Patients completing a hepatic metastasectomy
had an improved overall survival, P < 0.001. (b) Survival by a
hepatic metastasectomy in the current cohort (2002–2009).
Patients completing a hepatic metastasectomy had an improved
overall survival, P < 0.001
Table 3 Multivariable Cox’s proportional hazards model for overall
survival
HR 95% CI P-value
Age at diagnosisa 1.03 1.03–1.03 <0.001
Female sex 0.99 0.97–1.01 0.441
Race
African American 0.98 0.94–1.02 0.329
Other 0.82 0.79–0.86 <0.001
Charlson/Deyo comorbidity index 1.07 1.06–1.08 <0.001
AJCC initial diagnosis stage II vs. I 1.07 1.01–1.12 0.023
AJCC initial diagnosis stage III vs. I 1.39 1.32–1.46 <0.001
AJCC initial diagnosis stage IV vs. I 1.63 1.56–1.72 <0.001
Hepatic resection 0.40 0.38–0.42 <0.001
Chemotherapy 0.64 0.63–0.66 <0.001
Current study cohort 0.88 0.86–0.90 <0.001
aEstimates of effects of age to one thousandth: HR = 1.029, 95% CI:
1.028–1.031, P < 0.001.
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Proposed barriers to the delivery of population-level care
include existing or perceived burden of disease, demographic
or socioeconomic disparities, perceived morbidity of treatment
and patient comorbidity, and a lack of education about the
efficacy of a resection and/or referral patterns. Unlike recent
data suggesting disparities in treatment associated with insur-
ance disparities,21 all patients in this study were insured. With
advances in chemotherapy regimens, targeted therapy options,
as well as, operative and re-operative techniques, metastatic
colorectal cancer has been described as a chronic disease.22–25
On-going efforts should focus on the emphasis of multidisci-
plinary approaches and the multimodality treatment of patients
with colorectal cancer hepatic metastases.
Conclusion
Hepatic resection rates and the use of peri-operative
chemotherapy for patients with hepatic metastases from col-
orectal cancer continue to improve among Medicare recipients.
Despite advanced age and comorbidities, overall survival is
improved in patients selected for metastasectomy. Both a hep-
atic resection and systemic chemotherapy are associated with
improved survival.
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